Dare Bioscience Inc
NASDAQ:DARE
Dare Bioscience Inc
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2014-04-10. The firm is focused on advancing products for women's health. The company offers a portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Its first product, XACIATO, is a vaginal gel used for the treatment of bacterial vaginosis in females having 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-RH1, ADARE-204, and ADARE-214. Ovaprene, is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2014-04-10. The firm is focused on advancing products for women's health. The company offers a portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Its first product, XACIATO, is a vaginal gel used for the treatment of bacterial vaginosis in females having 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-RH1, ADARE-204, and ADARE-214. Ovaprene, is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.
DARE to PLAY Launch: Daré remains on track to launch DARE to PLAY Sildenafil Cream via a 503B outsourcing facility by the end of 2025, with initial prescriptions expected in select states in December and nationwide availability planned for early 2026.
Revenue Generation: Daré anticipates initial commercial revenue from DARE to PLAY beginning in the fourth quarter of 2025, marking a key milestone in its dual path strategy.
Pipeline Progress: The company continues to advance its grant-funded clinical pipeline, including Ovaprene (Phase III contraceptive), DARE-HPV (HPV therapy), and other preclinical contraception programs.
Strong Cash Position: Daré ended Q3 2025 with $23 million in cash and cash equivalents, bolstered by $18.7 million in stock sale proceeds and $7.3 million in grant payments during the quarter.
R&D Spend Down: R&D expenses fell by 56% year-over-year due to increased nondilutive funding and lower Ovaprene manufacturing and personnel costs.
Dual Path Strategy: The company is pursuing both 503B compounding and traditional FDA approval for several products, aiming to accelerate access while seeking long-term regulatory milestones.
Hormone Therapy Opportunity: Management expressed optimism about recent FDA policy changes around hormone replacement therapy, seeing strong provider enthusiasm for its DARE to RECLAIM vaginal ring product targeted for early 2027.
